Current management of cervical cancer in women living with HIV

IF 5.5 2区 医学 Q1 HEMATOLOGY Critical reviews in oncology/hematology Pub Date : 2024-09-24 DOI:10.1016/j.critrevonc.2024.104519
Evelyn Lilian Beas-Lozano , Sergio Contreras , Maria Andrea Mac Donald-Jaramillo , Citlali Frayde-Aguilar , Javier Carrillo-Vidales , Salvador Jaime-Casas , Bertha Alejandra Martinez-Cannon
{"title":"Current management of cervical cancer in women living with HIV","authors":"Evelyn Lilian Beas-Lozano ,&nbsp;Sergio Contreras ,&nbsp;Maria Andrea Mac Donald-Jaramillo ,&nbsp;Citlali Frayde-Aguilar ,&nbsp;Javier Carrillo-Vidales ,&nbsp;Salvador Jaime-Casas ,&nbsp;Bertha Alejandra Martinez-Cannon","doi":"10.1016/j.critrevonc.2024.104519","DOIUrl":null,"url":null,"abstract":"<div><div>Cervical cancer is a significant global health issue, particularly in low- and middle-income countries. Women living with HIV (WLWH) are not only at higher risk of cervical cancer due to their increased susceptibility to high-risk human papillomavirus (HPV) infection and compromised immune status, but also higher mortality rates have been reported. Therefore, prevention, optimal screening, use of highly active antiretroviral therapy (HAART), and early access to treatment are of utmost importance in this population. While international guidelines for cervical cancer state no treatment differences should be made for WLWH, there is evidence that this population of patients represents a challenge in decision-making for medical oncologists, radiation oncologists, and surgical oncologists. This review summarizes the available evidence on the different treatment strategies for WLWH and invasive cervical cancer and highlights the need for special considerations in screening andprevention of cervical cancer in WLWH.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104519"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002622","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cervical cancer is a significant global health issue, particularly in low- and middle-income countries. Women living with HIV (WLWH) are not only at higher risk of cervical cancer due to their increased susceptibility to high-risk human papillomavirus (HPV) infection and compromised immune status, but also higher mortality rates have been reported. Therefore, prevention, optimal screening, use of highly active antiretroviral therapy (HAART), and early access to treatment are of utmost importance in this population. While international guidelines for cervical cancer state no treatment differences should be made for WLWH, there is evidence that this population of patients represents a challenge in decision-making for medical oncologists, radiation oncologists, and surgical oncologists. This review summarizes the available evidence on the different treatment strategies for WLWH and invasive cervical cancer and highlights the need for special considerations in screening andprevention of cervical cancer in WLWH.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
目前对感染艾滋病毒妇女宫颈癌的管理。
宫颈癌是一个重大的全球健康问题,尤其是在中低收入国家。感染艾滋病毒的妇女(WLWH)不仅因其对高危人乳头瘤病毒(HPV)感染的易感性和受损的免疫状态而面临患宫颈癌的更高风险,而且据报道其死亡率也更高。因此,预防、最佳筛查、使用高活性抗逆转录病毒疗法(HAART)以及尽早接受治疗对这一人群至关重要。虽然宫颈癌的国际指南规定,WHLH 的治疗方法不应有所区别,但有证据表明,这部分患者对肿瘤内科医生、肿瘤放射科医生和肿瘤外科医生的决策构成了挑战。本综述强调了艾滋病病毒对人类乳头瘤病毒(HPV)感染(宫颈癌的主要病因)自然史的影响,并强调在筛查、预防和治疗白血病患者宫颈癌时需要特别注意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
3.20%
发文量
213
审稿时长
55 days
期刊介绍: Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.
期刊最新文献
Editorial Board Erratum to “Unleashing precision: A review of targeted approaches in pleural mesothelioma” [Crit. Rev. Oncol./Hematol. 203C (2024) 104481] Corrigendum to “The emerging HER2 landscape in Colorectal Cancer: The key to unveil the future treatment algorithm?” [Crit. Rev. Oncol./Hematol. 204 (2024) 104515] Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404] Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1